argenx SEARGX -0.17%80 Gross Margin % is 90.68% as of Mar. 2026, which is 1% above its 10-year median of 90.01. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,363.68 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 736 Biotechnology companies, argenx SE ranks better than 83.7% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. argenx SE's Gross Profit for the
three
months ended in Mar. 2026 was $1,177 Mil. argenx SE's Revenue for the
three
months ended in Mar. 2026 was $1,298 Mil. Therefore, argenx SE's Gross Margin % for the quarter that ended in Mar. 2026 was 90.68%.
The historical rank and industry rank for argenx SE's Gross Margin % or its related term are showing as below:
ARGX'
s Gross Margin % Range Over the Past 10 Years
Min: 89.15 Med: 90.01 Max: 92.83
Current: 89.47
During the past 13 years, the highestGross Margin % of argenx SE was 92.83%. The lowest was 89.15%. And the median was 90.01%.
ARGX's Gross Margin % is ranked better than 83.7% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs ARGX: 89.47
argenx SE had a gross margin of 90.68% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for argenx SE was 0.00% per year.
argenx SE (NAS:ARGX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
argenx SE had a gross margin of 90.68% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
argenx SE Gross Margin % Related Terms
argenx SE Gross Margin % Historical Data
* Premium members only.
The historical data trend for argenx SE's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARGX vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, argenx SE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Gross Margin % distribution charts can be found below:
* The bar in red indicates where argenx SE's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
argenx SE (ARGX) has a Gross Margin % of 90.68% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on argenx SE and its competitors. This is near median its historical median of 90.01. Over the past decade, argenx SE's Gross Margin % has ranged from 89.15 to 92.83. According to the industry distribution chart, argenx SE ranks #120 out of 736 companies in the Biotechnology industry, placing it in the top 16.3%.
Is argenx SE's Gross Margin % too high?
argenx SE's current Gross Margin % of 90.68% is near median its 10-year median of 90.01. Over the past 10 years, this metric has ranged from a low of 89.15 to a high of 92.83. The Biotechnology industry median Gross Margin % is 60.91. argenx SE's value of 90.68% is 48.9% above this industry median. Based on the distribution chart, argenx SE ranks #120 out of 736 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #120 out of 736 companies for Gross Margin %. This places argenx SE in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. argenx SE's value of 90.68% is 48.9% above this benchmark. Historically, argenx SE's own Gross Margin % has ranged from 89.15 to 92.83 over the past decade. While the company's 10-year median is 90.01 vs. the industry median of 60.91, argenx SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Gross Margin % of 90.68% is 48.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Gross Margin % is 90.68%, which is near median its own 10-year median of 90.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,363.68, compared to a current price of $885.80 — trading 35% below its estimated fair value. The current Gross Margin % is 90.68%, which is near median its 10-year median of 90.01 and 48.9% above the Biotechnology industry median of 60.91. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For argenx SE (ARGX), the current Gross Margin % is 90.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $885.80 is trading 35% below its estimated GF Value™ of $1,363.68.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Gross Margin %: 90.68% (near median its 10-year median of 90.01)
GF Value™: $1,363.68 vs. price of $885.80 (35% below fair value)
Industry Position: 48.9% above the Biotechnology median (#120 of 736)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score
Get the complete analysis for ARGX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
